Loading organizations...
Key people at Genvax Technologies, Inc.
Based in Ames, Iowa, Genvax Technologies, Inc is a biotechnology startup that develops self-amplifying mRNA and nanoparticle vaccines for the animal health and livestock sectors. The company focuses on creating preventative treatments for zoonotic threats and agricultural diseases, specifically targeting severe conditions such as swine influenza and African Swine Fever. The leadership team previously built Harrisvaccines, an enterprise utilizing licensed replicon technology from AlphaVax that secured multiple USDA approvals before being acquired by Merck Animal Health in 2015. While specific corporate metrics such as total funding raised, employee count, and current valuation remain undisclosed, the executive team maintains strong industry ties through leadership roles at the Ag Startup Engine. Through this accelerator, the founders actively support a broader portfolio of emerging agricultural technology ventures. Genvax Technologies, Inc was founded in 2021 by Joel Harris and Dr. Hank Harris.
Genvax Technologies, Inc. is an early-stage biotech startup based in Ames, Iowa, developing next-generation self-amplifying RNA (saRNA) vaccines for animal health. The company creates rapid-response, 100% strain-matched vaccines for production livestock, targeting endemic and emerging diseases like African Swine Fever and swine influenza, while eliminating the need for costly, ineffective traditional vaccine stockpiles.[1][2][4] It serves livestock producers by adapting human healthcare advances—such as saRNA platforms and nanoparticle delivery—to animal applications, addressing zoonotic threats that impact both animal and human health.[2][3]
Founded in 2021, Genvax has demonstrated proof-of-concept in pigs, secured USDA grants for key vaccine developments, and initiated regulatory submissions, positioning it for potential commercialization in 2-3 years.[2]
Genvax Technologies was founded in 2021 by vaccine industry veterans Joel Harris (CEO and co-founder) and Dr. Hank Harris, both serial entrepreneurs who previously built and sold Harrisvaccines to Merck Animal Health in 2015.[2] Drawing from their experience in animal vaccines, the duo launched Genvax to bridge innovations from human mRNA vaccines—proven during COVID-19—back to animal health, where 70% of diseases are zoonotic and rapidly evolving threats like African Swine Fever demand faster solutions.[2]
Early traction includes proof-of-concept studies in pigs, grant funding from USDA-ARS Plum Island Animal Disease Center, Foundation for Food and Agriculture Research (FFAR), and a USDA SBIR grant for swine influenza vaccines, alongside initial USDA product approval submissions.[2]
Genvax rides the mRNA revolution post-COVID, adapting self-amplifying RNA and nanoparticle delivery from human vaccines to animal agriculture, where diseases evolve quickly and impact food security.[2][3] Timing is ideal amid rising zoonotic outbreaks (e.g., African Swine Fever, swine flu), with market forces like USDA funding and regulatory pathways favoring agile platforms over traditional methods.[2]
By enabling precise, on-demand vaccines, Genvax influences the livestock ecosystem, reducing economic losses from disease (billions annually) and supporting sustainability in protein production, while contributing to global One Health initiatives against pandemics.[1][2]
Genvax is poised for milestones in USDA approvals over the next 2-3 years, with grants fueling pipeline expansion into more livestock diseases and potential partnerships like its founders' prior Merck deal.[2] Trends in RNA tech scalability, AI-driven strain matching, and biomanufacturing will accelerate growth, potentially drawing investment from ag-tech VCs amid private market interest.[3]
As zoonotics intensify with climate shifts, Genvax could redefine animal health resilience, scaling from Iowa startup to a Merck-like acquisition target and bolstering the saRNA ecosystem for faster, targeted defenses.
Key people at Genvax Technologies, Inc.
